Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-100IT in Acute Spinal Cord Injury
NCT07722962Phase 3Not yet recruiting
- Sponsor
- Kringle Pharma, Inc.
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of KP-100 in spinal cord injury (SCI), sponsored by Kringle Pharma, Inc.. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
KP-100
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT07722962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722962.